Lottery.com stock steadies premarket after 80% surge, volatility pause puts SEGG in focus

Lottery.com stock steadies premarket after 80% surge, volatility pause puts SEGG in focus

New York, Jan 15, 2026, 05:34 EST — Premarket

  • SEGG was last around $0.93 in premarket trading after a sharp jump in the prior session.
  • The stock closed Wednesday up nearly 80% on unusually heavy volume and saw a mid-session volatility pause.
  • Traders are watching for any company disclosure and the next earnings update later this quarter.

Lottery.com Inc shares were little changed in premarket trading on Thursday, holding near $0.93 after a blistering run in the prior session that put the microcap back on traders’ screens.

The jump matters because SEGG normally trades like a thin, low-priced name. When volume suddenly spikes, price can gap hard and liquidity can vanish just as quickly, especially around the open.

It also leaves investors with a simple question: was Wednesday’s move tied to fresh news, or was it a momentum burst that could unwind just as fast once the bell rings.

SEGG closed on Wednesday at $0.93, up 79.91% from the prior close, after swinging between $0.79 and $1.44. About 329.83 million shares traded, compared with roughly 122,673 shares the day before, MarketBeat data showed. (MarketBeat)

Nasdaq paused trading in the stock at 12:23 p.m. ET on Wednesday for a volatility trading pause, a Reuters headline carried by TradingView showed. Such pauses are triggered under “limit up-limit down” rules, which briefly stop trading when prices move too far, too fast. (TradingView)

The company has not given a public explanation tied to the surge. An earlier regulatory update this month covered board committee assignments, an SEC filing showed.

Lottery.com, which now trades on Nasdaq under the ticker SEGG after a symbol change from LTRY last year, runs a platform that enables remote purchase of lottery games where permitted. (Investing)

But the stock’s tape action sits on top of a fragile backdrop. In its latest quarterly report, the company said it will need additional capital and warned that conditions “raise substantial doubt” about its ability to continue as a going concern.

For Thursday’s session, traders will be watching whether volume holds anywhere close to Wednesday’s level and whether the stock revisits the $1 area early, a zone that often draws fast money in low-priced names.

Beyond the opening swings, the next scheduled marker is the company’s earnings report, which TradingView lists for Feb. 25. Any update on funding, operations or strategy would likely carry extra weight after this week’s volatility. (TradingView)

Stock Market Today

  • BridgeBio Pharma Valuation After Attruby Uptake, BBP-418 Data, and Late-Stage Pipeline Momentum
    January 15, 2026, 6:33 AM EST. BridgeBio Pharma (BBIO) has drawn fresh attention after reporting more than 6,600 prescriptions for its ATTR-CM therapy Attruby, releasing interim Phase 3 data for BBP-418, and outlining a new TTR amyloid depleter program. Our latest analysis notes a 90-day share-price gain of 41.6% and a 3-year total shareholder return, with the stock near US$77.90. The fair value estimate stands around US$84.65, implying upside if late-stage programs convert to revenue and earnings. Analysts' consensus price target is US$63.81, with a range from US$41.00 to US$95.00. Risks include durability of Attruby, negative trial data, and regulatory delays. Valuation shows BridgeBio trading at a discount to our fair value, but a high P/S ratio (~42.4x vs 26.8x fair). A premium valuation hinges on execution and margin expansion.
AppLovin stock (APP) steadies in premarket after a brutal slide — Evercore’s new buy call is the test
Previous Story

AppLovin stock (APP) steadies in premarket after a brutal slide — Evercore’s new buy call is the test

Broadcom stock falls again as China targets VMware; RBC says OpenAI upside ‘less clear’
Next Story

Broadcom stock falls again as China targets VMware; RBC says OpenAI upside ‘less clear’

Go toTop